indolent systemic mastocytosis
Information
- Disease name
- indolent systemic mastocytosis
- Disease ID
- DOID:4660
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03731260 | Active, not recruiting | Phase 2 | (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis | April 16, 2019 | January 31, 2028 |
| NCT02478957 | Completed | Phase 2 | Treatment of Indolent Systemic Mastocytosis With PA101 | June 2015 | June 2016 |
| NCT02808793 | Completed | Phase 1 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 | June 2016 | December 2018 |
| NCT03632811 | Completed | Adaptation of the Questionnaire "Regarding Patient's Quality of Life With Mastocytosis" in the French Language | November 14, 2018 | November 21, 2018 | |
| NCT00814073 | Completed | Phase 3 | Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis | December 2008 | November 2015 |
| NCT03770273 | Completed | Phase 2 | Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis | June 19, 2019 | July 31, 2023 |
| NCT06210698 | Not yet recruiting | Angioedema Biomarker Research Study | January 15, 2024 | February 1, 2026 | |
| NCT04333108 | Recruiting | Phase 3 | Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment | July 1, 2020 | June 2025 |
| NCT04655118 | Recruiting | Phase 2 | Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis | October 22, 2020 | December 31, 2025 |
| NCT04910685 | Recruiting | Phase 2/Phase 3 | (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis | November 30, 2021 | June 30, 2028 |
| NCT01920204 | Unknown status | Phase 2 | Midostaurin in Indolent Systemic Mastocytosis | August 2013 | May 2015 |
- Disase is a (Disease Ontology)
- DOID:349
- Cross Reference ID (Disease Ontology)
- ICD10CM:D47.02
- Cross Reference ID (Disease Ontology)
- ICDO:9741/1
- Cross Reference ID (Disease Ontology)
- MESH:D034721
- Cross Reference ID (Disease Ontology)
- NCI:C9286
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:70910003
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0272203
- Exact Synonym (Disease Ontology)
- ISM
- OrphaNumber from OrphaNet (Orphanet)
- 98848